BMRA - Biomerica Inc Stock Price, Fair Value and News

0.56USD-0.04 (-6.67%)Delayed

Market Summary

USD0.56-0.04

Delayed

-6.67%

BMRA Stock Price

View Fullscreen

BMRA RSI Chart

BMRA Valuation

Market Cap

9.4M

Price/Earnings (Trailing)

-1.48

Price/Sales (Trailing)

2.55

EV/EBITDA

-0.66

Price/Free Cashflow

-1.78

BMRA Price/Sales (Trailing)

BMRA Profitability

Operating Margin

10.31%

EBT Margin

-118.02%

Return on Equity

-81.32%

Return on Assets

-61.39%

Free Cashflow Yield

-56.33%

BMRA Fundamentals

BMRA Revenue

Revenue (TTM)

5.3M

Rev. Growth (Yr)

-8.5%

Rev. Growth (Qtr)

-35.1%

BMRA Earnings

Earnings (TTM)

-6.3M

Earnings Growth (Yr)

-16.25%

Earnings Growth (Qtr)

-27.27%

Breaking Down BMRA Revenue

Last 7 days

-16.4%

Last 30 days

-32.5%

Last 90 days

-38.5%

Trailing 12 Months

-59.4%

How does BMRA drawdown profile look like?

BMRA Financial Health

Current Ratio

4.44

BMRA Investor Care

Diluted EPS (TTM)

-0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	9.5M	5.3M	0	0
2022	14.6M	18.9M	19.2M	16.1M
2021	8.9M	7.2M	7.3M	10.6M
2020	5.1M	6.7M	6.6M	6.4M
2019	5.2M	5.2M	5.1M	5.2M
2018	5.9M	5.6M	5.4M	5.3M
2017	5.7M	5.8M	5.8M	6.0M
2016	5.3M	5.1M	5.3M	5.5M
2015	5.1M	5.0M	5.2M	5.2M
2014	4.9M	5.1M	5.1M	5.3M
2013	6.5M	6.5M	5.8M	4.8M
2012	5.8M	6.1M	6.4M	6.6M
2011	0	4.9M	5.1M	5.6M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biomerica Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 25, 2023	irani zackary s.	bought	310	1.55	200	chief executive officer
May 24, 2023	irani zackary s.	bought	805	1.61	500	chief executive officer
May 12, 2023	irani zackary s.	bought	1,989	1.17	1,700	chief executive officer
May 10, 2023	irani zackary s.	bought	635	1.27	500	chief executive officer
May 09, 2023	irani zackary s.	bought	417	1.39	300	chief executive officer
May 04, 2023	irani zackary s.	bought	1,360	1.36	1,000	chief executive officer
Apr 28, 2023	irani zackary s.	bought	2,412	1.34	1,800	chief executive officer
Apr 27, 2023	irani zackary s.	bought	3,406	1.31	2,600	chief executive officer
Apr 26, 2023	irani zackary s.	bought	8,820	1.26	7,000	chief executive officer
Jan 27, 2023	barbieri allen	bought	4,521	2.94	1,538	executive vice chairman

Which funds bought or sold BMRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	HOLLENCREST CAPITAL MANAGEMENT	added	55.52	362	10,675	-%
Apr 29, 2024	HERITAGE INVESTORS MANAGEMENT CORP	unchanged	-	-14,000	29,000	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	unchanged	-	-6,061	12,064	-%
Apr 18, 2024	WASATCH ADVISORS LP	unchanged	-	-398,464	793,116	-%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-125	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	7.56	274,375	761,706	-%
Feb 15, 2024	Potomac Capital Management, Inc.	reduced	-2.23	62,084	209,625	0.24%
Feb 14, 2024	LPL Financial LLC	new	-	18,969	18,969	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	14,591	46,539	-%

Are Funds Buying or Selling BMRA?

Are funds buying BMRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BMRA

No. of Funds

Unveiling Biomerica Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	granahan investment management, llc	6.44%	1,082,672	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G
Feb 14, 2023	granahan investment management, llc	8.36%	1,122,701	SC 13G/A
Feb 14, 2022	granahan investment management, llc	8.81%	1,102,573	SC 13G
Feb 04, 2022	wellington management group llp	0.00%	0	SC 13G/A
Feb 04, 2022	wellington trust co n a	0.00%	0	SC 13G/A
Feb 04, 2022	wellington trust company, national association multiple common trust funds trust, micro cap equity p	0.00%	0	SC 13G/A
Feb 03, 2021	wellington management group llp	7.37%	866,000	SC 13G
Feb 03, 2021	wellington trust co n a	7.37%	866,000	SC 13G
Feb 03, 2021	wellington trust company, national association multiple common trust funds trust, micro cap equity p	6.15%	723,200	SC 13G/A

Recent SEC filings of Biomerica Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	10-Q	Quarterly Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Biomerica Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.2B	40.3B	-4.83%	-4.47%	32.75	4.57	-2.84%	-3.08%
BDX	67.8B	19.7B	-3.67%	-7.05%	50.87	3.44	4.82%	-17.56%
ALGN	21.7B	3.9B	-7.16%	-5.33%	46.88	5.53	5.72%	46.72%
BAX	18.8B	14.9B	-14.74%	-18.53%	7.1	1.26	2.98%	207.68%
MID-CAP
ATR	9.7B	3.5B	4.25%	23.63%	31.11	2.75	6.16%	35.06%
HSIC	8.7B	12.3B	-7.72%	-14.36%	20.93	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-14.65%	-39.45%	-12.84	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-11.18%	-30.75%	-62.82	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-3.46%	33.44%	-215.47	8.86	30.82%	65.60%
PDCO	2.3B	6.6B	-3.32%	-1.38%	11.88	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	-5.95%	-6.55%	-2.02	0.43	7.73%	-1066.14%
ANIK	408.8M	166.7M	4.91%	6.74%	-4.95	2.45	6.67%	-456.34%
ANGO	250.7M	324.0M	2.96%	-26.18%	-1.3	0.77	-3.19%	-337.41%
APYX	49.5M	52.3M	-10.06%	-59.60%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-19.65%	334.38%	-0.3	0.97	5.77%	8.23%

Biomerica Inc News

Latest updates

Biomerica Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-35.1%	1,017,000	1,567,000	1,337,583	1,108,166	1,111,442	1,482,000	1,637,435	5,301,656	7,660,501	4,647,000	1,262,000	1,054,042	3,628,638	1,372,526	1,143,806	2,724,999	1,176,889	1,596,408	1,194,415	1,165,860	1,261,161
Cost Of Revenue	-6.1%	1,166,000	1,242,000	1,301,000	1,079,616	991,169	1,130,000	1,692,000	4,680,825	5,987,277	3,875,141	1,350,757	1,041,149	3,702,069	1,063,807	1,025,717	2,034,927	964,910	1,127,536	827,111	985,053	895,237
Gross Profit	-145.8%	-149,000	325,000	412,000	28,767	120,273	352,000	-55,000	620,987	1,673,224	771,759	-88,970	12,908	-73,431	308,719	118,089	690,072	211,979	468,872	367,304	180,807	365,924
Operating Expenses	-4.2%	1,851,000	1,933,000	1,644,000	1,864,580	1,771,443	2,018,000	2,015,000	2,377,358	1,780,723	1,901,520	1,451,399	1,735,208	2,091,914	2,021,407	2,017,449	1,516,450	1,126,864	958,615	876,863	945,626	1,073,172
S&GA Expenses	-0.9%	1,508,000	1,521,000	1,172,000	1,495,667	1,379,412	1,556,000	1,654,000	1,881,939	1,393,619	1,353,587	1,069,855	1,432,780	1,527,947	1,404,846	1,305,944	832,479	653,585	553,761	506,397	536,816	576,070
R&D Expenses	-16.7%	343,000	412,000	472,000	368,985	392,031	462,000	361,000	495,243	387,000	547,933	382,000	301,951	564,000	616,561	711,505	683,971	473,279	404,854	370,466	408,810	497,102
EBITDA Margin	-5.0%	-1.17	-1.11	-1.13	-1.31	-0.71	-0.33	-0.24	-0.22	-0.30	-0.60	-0.95	-1.01	-0.72	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	111	256	-	-	-1.00	5.00	5.00	-	-	-
Income Taxes	-50.0%	4,000	8,000	23,000	13,120	34,775	1,000	2,000	9,866	2,688	2,429	9,017	1,599	-3,117	13,393	1,125	-4,780	4,326	7,044	800	-	-
Earnings Before Taxes	-27.7%	-1,914,000	-1,499,000	-1,109,000	-1,779,039	-1,615,084	-1,625,000	-2,070,000	-1,749,111	-101,480	-1,122,845	-1,533,564	-1,709,565	-2,127,658	-1,704,705	-1,891,269	-817,699	-860,926	-485,260	-505,496	-761,093	-678,746
EBT Margin	-5.0%	-1.18	-1.12	-1.15	-1.33	-0.74	-0.34	-0.26	-0.24	-0.31	-0.61	-0.97	-1.03	-0.74	-	-	-	-	-	-	-	-
Net Income	-27.3%	-1,918,000	-1,507,000	-1,132,000	-1,792,159	-1,649,859	-1,626,000	-2,072,000	-1,758,977	-104,168	-1,125,274	-1,542,581	-1,711,221	-2,124,541	-1,718,098	-1,892,394	-824,689	-860,926	-485,260	-506,296	-785,330	-678,746
Net Income Margin	-4.4%	-1.19	-1.14	-1.16	-1.34	-0.75	-0.35	-0.26	-0.24	-0.31	-0.61	-0.97	-1.03	-0.74	-	-	-	-	-	-	-	-
Free Cashflow	-112.4%	-1,801,000	-848,000	-1,695,000	-962,817	-1,731,183	-1,237,000	-1,607,000	-4,280,499	2,343,961	1,329,843	70,695	-1,036,780	-1,409,040	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.6%	10,342	11,831	13,219	14,454	8,210	9,908	11,050	11,374	17,560	14,809	11,516	11,819	13,348	14,478	15,892	17,260	8,215	7,039	6,724	5,245	5,068
Current Assets	-13.8%	8,846	10,265	11,574	12,797	6,482	8,099	9,168	9,427	15,231	12,403	8,946	9,231	10,785	11,947	13,120	14,767	5,739	4,511	4,114	4,495	4,329
Cash Equivalents	-25.4%	5,319	7,134	7,988	9,719	3,345	5,067	6,075	5,917	10,174	7,199	4,997	4,199	5,273	5,684	6,964	8,641	2,392	851	808	687	918
Inventory	15.6%	2,129	1,841	1,877	2,056	2,064	2,061	1,922	2,416	3,231	2,982	2,862	3,206	2,860	4,198	4,101	2,851	2,188	2,191	2,206	2,151	2,080
Net PPE	-7.6%	194	210	218	213	228	237	228	214	263	274	288	311	308	288	292	279	301	304	324	351	346
Liabilities	3.5%	2,534	2,448	2,451	2,730	2,224	2,665	2,728	3,049	7,803	5,908	2,713	2,592	2,748	3,329	3,312	3,047	3,534	3,663	3,100	1,264	-
Current Liabilities	9.3%	1,991	1,822	1,746	1,945	1,395	1,763	1,758	2,011	6,698	4,741	1,482	1,300	1,352	1,874	1,801	1,477	1,910	1,984	1,369	1,264	1,113
Shareholder's Equity	-16.8%	7,808	9,383	10,768	11,724	5,986	7,244	8,322	8,325	9,758	8,901	8,803	9,228	10,600	11,149	12,581	14,213	4,681	3,376	3,624	3,981	3,954
Retained Earnings	-4.3%	-46,774	-44,856	-43,349	-42,217	-40,400	-38,800	-37,149	-35,077	-33,300	-33,214	-32,088	-30,546	-26,899	-25,060	-23,575	-23,100	-21,439	-20,578	-20,092	-19,586	-18,801
Additional Paid-In Capital	0.6%	53,338	52,997	52,875	52,705	45,443	45,035	44,485	42,447	42,109	41,159	39,945	38,837	36,564	35,285	35,231	36,388	26,447	23,223	22,975	22,830	22,049
Accumulated Depreciation	-	-	-	-	-	1,316	1,317	1,326	1,305	2,047	2,027	2,000	1,972	1,946	1,920	1,894	1,868	1,689	1,814	1,792	1,762	1,739
Shares Outstanding	0%	16,822	16,822	16,822	16,822	13,488	13,455	13,100	12,868	12,612	12,509	12,427	12,307	11,803	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	42,738	-	-	-	55,710	-	-	-	66,939	-	-	-	23,398	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-113.9%	-1,801	-842	-1,674	-962	-1,725	-1,213	-1,573	-4,256	2,358	1,343	76.00	-1,007	-1,363	-1,283	-1,597	-3,494	-436	-357	-8.15	-986	-256
Share Based Compensation	179.5%	341	122	170	179	384	318	304	301	325	314	320	-	-	-	-	-	-	-	-	-	-
Cashflow From Investing	-33.3%	-16.00	-12.00	-63.00	-14.14	-5.86	-24.00	-34.00	-24.02	-18.85	-49.61	-77.52	-71.94	-100	-30.36	-92.75	-67.27	-30.33	-7.06	-14.27	-51.94	-34.16
Cashflow From Financing	-	-	-	-	7,350	25.00	237	1,778	38.00	638	914	805	6.00	1,059	34.00	15.00	9,810	2,007	410	147	810	85.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BMRA Income Statement

2024-02-29

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Feb. 28, 2023	Feb. 29, 2024	Feb. 28, 2023
Income Statement [Abstract]
Net sales	$ 1,017,000	$ 1,111,000	$ 4,299,000	$ 4,231,000
Cost of sales	(1,166,000)	(991,000)	(3,708,000)	(3,814,000)
Gross (loss) profit	(149,000)	120,000	591,000	417,000
Operating expenses:
Selling, general and administrative	1,508,000	1,379,000	4,204,000	4,589,000
Research and development	343,000	392,000	1,226,000	1,215,000
Total operating expenses	1,851,000	1,771,000	5,430,000	5,804,000
Loss from operations	(2,000,000)	(1,651,000)	(4,839,000)	(5,387,000)
Other income:
Interest and dividend income	86,000	36,000	317,000	77,000
Total other income	86,000	36,000	317,000	77,000
Loss before income taxes	(1,914,000)	(1,615,000)	(4,522,000)	(5,310,000)
Provision (benefit) for income taxes	(4,000)	(35,000)	(35,000)	(38,000)
Net loss	$ (1,918,000)	$ (1,650,000)	$ (4,557,000)	$ (5,348,000)
Basic net loss per common share	$ (0.11)	$ (0.12)	$ (0.27)	$ (0.40)
Diluted net loss per common share	$ (0.11)	$ (0.12)	$ (0.27)	$ (0.40)
Weighted average number of common and common equivalent shares:
Basic	16,821,646	13,481,490	16,821,646	13,341,000
Diluted	16,821,646	13,481,490	16,821,646	13,341,000
Net loss	$ (1,918,000)	$ (1,650,000)	$ (4,557,000)	$ (5,348,000)
Other comprehensive income (loss), net of tax:
Foreign currency translation	2,000	(15,000)	8,000	(37,000)
Comprehensive loss	$ (1,916,000)	$ (1,665,000)	$ (4,549,000)	$ (5,385,000)

BMRA Balance Sheet

2024-02-29

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Feb. 29, 2024	May 31, 2023
Current Assets:
Cash and cash equivalents	$ 5,319,000	$ 9,719,000
Accounts receivable, net	1,130,000	722,000
Inventories, net	2,129,000	2,056,000
Prepaid expenses and other	268,000	300,000
Total current assets	8,846,000	12,797,000
Property and equipment, net of accumulated depreciation and amortization	194,000	213,000
Right-of-use assets, net of accumulated amortization of $835,000 and $617,000 as of February 29, 2024 and May 31, 2023, respectively	817,000	1,035,000
Investments	165,000	165,000
Intangible assets, net of accumulated amortization of $44,000 and $30,000 as of February 29, 2024 and May 31, 2023, respectively	216,000	165,000
Other assets	104,000	79,000
Total Assets	10,342,000	14,454,000
Current Liabilities:
Accounts payable and accrued expenses	885,000	892,000
Accrued compensation	702,000	696,000
Advance from customers	85,000	60,000
Lease liabilities, current portion	319,000	297,000
Total current liabilities	1,991,000	1,945,000
Lease liabilities, net of current portion	543,000	785,000
Total Liabilities	2,534,000	2,730,000
Commitments and contingencies (Note 6)
Shareholders’ Equity:
Preferred stock, value
Common stock, $0.08 par value, 25,000,000 shares authorized, 16,821,646 issued and outstanding at February 29, 2024 and May 31, 2023, respectively	1,346,000	1,346,000
Additional paid-in capital	53,338,000	52,705,000
Accumulated other comprehensive loss	(102,000)	(110,000)
Accumulated deficit	(46,774,000)	(42,217,000)
Total Shareholders’ Equity	7,808,000	11,724,000
Total Liabilities and Shareholders’ Equity	10,342,000	14,454,000
Series A Preferred Stock [Member]
Shareholders’ Equity:
Preferred stock, value

About Biomerica Inc

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

CEO	Mr. Zackary S. Irani
WEBSITE	biomerica.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	62

Biomerica Inc Frequently Asked Questions

What is the ticker symbol for Biomerica Inc? What does BMRA stand for in stocks?

BMRA is the stock ticker symbol of Biomerica Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biomerica Inc (BMRA)?

As of Fri May 03 2024, market cap of Biomerica Inc is 9.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMRA stock?

You can check BMRA's fair value in chart for subscribers.

What is the fair value of BMRA stock?

You can check BMRA's fair value in chart for subscribers. The fair value of Biomerica Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biomerica Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BMRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biomerica Inc a good stock to buy?

The fair value guage provides a quick view whether BMRA is over valued or under valued. Whether Biomerica Inc is cheap or expensive depends on the assumptions which impact Biomerica Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMRA.

What is Biomerica Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, BMRA's PE ratio (Price to Earnings) is -1.48 and Price to Sales (PS) ratio is 2.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMRA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biomerica Inc's stock?

In the past 10 years, Biomerica Inc has provided 0.015 (multiply by 100 for percentage) rate of return.